Search alternatives:
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1041
The percentage of tPSA levels over 20 ng/mL in PCa patients.
Published 2013“…<p>There was a significant decrease in the percentage of tPSA levels over 20 ng/mL in PCa patients from 2003 to 2010 (<i>P<sub>trend</sub></i> = 2.26×10<sup>−5</sup>).…”
-
1042
-
1043
-
1044
-
1045
-
1046
-
1047
-
1048
-
1049
-
1050
-
1051
-
1052
Scatter plot for the absolute decrease in CS rates (A) and the relative decrease in CS rates (B) from 2008 to 2016 among hospitals in Guangzhou grouped by their baseline CS rates.
Published 2019“…One circle represents one hospital, with blue (<i>n</i> = 20), green (<i>n</i> = 36), orange (<i>n</i> = 34), and purple (<i>n</i> = 22) representing baseline CS rates of <30%, 30%–39%, 40%–49%, and ≥50%, respectively. The absolute decrease = the CS rate at baseline − the CS rate in Stage 2; the relative decrease = (the CS rate at baseline − the CS rate in Stage 2) ÷ the CS rate at baseline. …”
-
1053
DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
-
1054
-
1055
-
1056
-
1057
-
1058
-
1059
-
1060
In we present the number of modules determined by DMSP on various values of connectivity density
Published 2011“…In figure we display the initial size of the kernel, as well as the final size of the module, for modules with various sizes, and densities above 0.5. …”